Last reviewed · How we verify
Avandamet
At a glance
| Generic name | Avandamet |
|---|---|
| Also known as | Metformin plus rosiglitazone, Rosiglitazone and Metformin, metformin, sulphonylurea, rosiglitazone maleate and metformin hydrochloride |
| Sponsor | M.D. Anderson Cancer Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) (PHASE3)
- Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients. (PHASE2, PHASE3)
- Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM (NA)
- Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects (PHASE3)
- AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus (PHASE4)
- A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics (PHASE3)
- Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes (PHASE4)
- Avandamet Bioequivalence Study Brazil - Fed Administration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avandamet CI brief — competitive landscape report
- Avandamet updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI